With the discovery of critical mutations necessary for the growth and spread of tumours, particularly those involving the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), platinum-based chemotherapy has given way to a new era of molecular targeted therapy for the treatment of NSCLC [9, 10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.